Request Free Sample ×

Kindly complete the form below to receive a free sample of this Report

* Please use a valid business email

Leading companies partner with us for data-driven Insights

clients tt-cursor
Hero Background

Brachytherapy Treatment Planning System Market

ID: MRFR/Pharma/27378-HCR
128 Pages
Rahul Gotadki
Last Updated: April 06, 2026
Brachytherapy Treatment Planning System Market Research Report By Modality (Intracavitary, Interstitial, Intraluminal, Surface), By Application (Cancer, Benign conditions), By Treatment Type (High-dose-rate (HDR) Brachytherapy, Low-dose-rate (LDR) Brachytherapy) and By Regional (North America, Europe, South America, Asia Pacific, Middle East and Africa) - Growth & Industry Forecast 2025 To 2035
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

  1. 1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
    1. 1.1 EXECUTIVE SUMMARY
      1. 1.1.1 Market Overview
      2. 1.1.2 Key Findings
      3. 1.1.3 Market Segmentation
      4. 1.1.4 Competitive Landscape
      5. 1.1.5 Challenges and Opportunities
      6. 1.1.6 Future Outlook
  2. 2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
    1. 2.1 MARKET INTRODUCTION
      1. 2.1.1 Definition
      2. 2.1.2 Scope of the study
        1. 2.1.2.1 Research Objective
        2. 2.1.2.2 Assumption
        3. 2.1.2.3 Limitations
    2. 2.2 RESEARCH METHODOLOGY
      1. 2.2.1 Overview
      2. 2.2.2 Data Mining
      3. 2.2.3 Secondary Research
      4. 2.2.4 Primary Research
        1. 2.2.4.1 Primary Interviews and Information Gathering Process
        2. 2.2.4.2 Breakdown of Primary Respondents
      5. 2.2.5 Forecasting Model
      6. 2.2.6 Market Size Estimation
        1. 2.2.6.1 Bottom-Up Approach
        2. 2.2.6.2 Top-Down Approach
      7. 2.2.7 Data Triangulation
      8. 2.2.8 Validation
  3. 3 SECTION III: QUALITATIVE ANALYSIS
    1. 3.1 MARKET DYNAMICS
      1. 3.1.1 Overview
      2. 3.1.2 Drivers
      3. 3.1.3 Restraints
      4. 3.1.4 Opportunities
    2. 3.2 MARKET FACTOR ANALYSIS
      1. 3.2.1 Value chain Analysis
      2. 3.2.2 Porter's Five Forces Analysis
        1. 3.2.2.1 Bargaining Power of Suppliers
        2. 3.2.2.2 Bargaining Power of Buyers
        3. 3.2.2.3 Threat of New Entrants
        4. 3.2.2.4 Threat of Substitutes
        5. 3.2.2.5 Intensity of Rivalry
      3. 3.2.3 COVID-19 Impact Analysis
        1. 3.2.3.1 Market Impact Analysis
        2. 3.2.3.2 Regional Impact
        3. 3.2.3.3 Opportunity and Threat Analysis
  4. 4 SECTION IV: QUANTITATIVE ANALYSIS
    1. 4.1 Healthcare, BY Modality (USD Billion)
      1. 4.1.1 Intracavitary
      2. 4.1.2 Interstitial
      3. 4.1.3 Intraluminal
      4. 4.1.4 Surface
    2. 4.2 Healthcare, BY Application (USD Billion)
      1. 4.2.1 Cancer
      2. 4.2.2 Benign conditions
    3. 4.3 Healthcare, BY Treatment Type (USD Billion)
      1. 4.3.1 High-dose-rate (HDR) Brachytherapy
      2. 4.3.2 Low-dose-rate (LDR) Brachytherapy
    4. 4.4 Healthcare, BY Region (USD Billion)
      1. 4.4.1 North America
        1. 4.4.1.1 US
        2. 4.4.1.2 Canada
      2. 4.4.2 Europe
        1. 4.4.2.1 Germany
        2. 4.4.2.2 UK
        3. 4.4.2.3 France
        4. 4.4.2.4 Russia
        5. 4.4.2.5 Italy
        6. 4.4.2.6 Spain
        7. 4.4.2.7 Rest of Europe
      3. 4.4.3 APAC
        1. 4.4.3.1 China
        2. 4.4.3.2 India
        3. 4.4.3.3 Japan
        4. 4.4.3.4 South Korea
        5. 4.4.3.5 Malaysia
        6. 4.4.3.6 Thailand
        7. 4.4.3.7 Indonesia
        8. 4.4.3.8 Rest of APAC
      4. 4.4.4 South America
        1. 4.4.4.1 Brazil
        2. 4.4.4.2 Mexico
        3. 4.4.4.3 Argentina
        4. 4.4.4.4 Rest of South America
      5. 4.4.5 MEA
        1. 4.4.5.1 GCC Countries
        2. 4.4.5.2 South Africa
        3. 4.4.5.3 Rest of MEA
  5. 5 SECTION V: COMPETITIVE ANALYSIS
    1. 5.1 Competitive Landscape
      1. 5.1.1 Overview
      2. 5.1.2 Competitive Analysis
      3. 5.1.3 Market share Analysis
      4. 5.1.4 Major Growth Strategy in the Healthcare
      5. 5.1.5 Competitive Benchmarking
      6. 5.1.6 Leading Players in Terms of Number of Developments in the Healthcare
      7. 5.1.7 Key developments and growth strategies
        1. 5.1.7.1 New Product Launch/Service Deployment
        2. 5.1.7.2 Merger & Acquisitions
        3. 5.1.7.3 Joint Ventures
      8. 5.1.8 Major Players Financial Matrix
        1. 5.1.8.1 Sales and Operating Income
        2. 5.1.8.2 Major Players R&D Expenditure. 2023
    2. 5.2 Company Profiles
      1. 5.2.1 Elekta (SE)
        1. 5.2.1.1 Financial Overview
        2. 5.2.1.2 Products Offered
        3. 5.2.1.3 Key Developments
        4. 5.2.1.4 SWOT Analysis
        5. 5.2.1.5 Key Strategies
      2. 5.2.2 Varian Medical Systems (US)
        1. 5.2.2.1 Financial Overview
        2. 5.2.2.2 Products Offered
        3. 5.2.2.3 Key Developments
        4. 5.2.2.4 SWOT Analysis
        5. 5.2.2.5 Key Strategies
      3. 5.2.3 Brachytherapy Solutions (US)
        1. 5.2.3.1 Financial Overview
        2. 5.2.3.2 Products Offered
        3. 5.2.3.3 Key Developments
        4. 5.2.3.4 SWOT Analysis
        5. 5.2.3.5 Key Strategies
      4. 5.2.4 Nucletron (NL)
        1. 5.2.4.1 Financial Overview
        2. 5.2.4.2 Products Offered
        3. 5.2.4.3 Key Developments
        4. 5.2.4.4 SWOT Analysis
        5. 5.2.4.5 Key Strategies
      5. 5.2.5 CIVCO Medical Solutions (US)
        1. 5.2.5.1 Financial Overview
        2. 5.2.5.2 Products Offered
        3. 5.2.5.3 Key Developments
        4. 5.2.5.4 SWOT Analysis
        5. 5.2.5.5 Key Strategies
      6. 5.2.6 IBA (BE)
        1. 5.2.6.1 Financial Overview
        2. 5.2.6.2 Products Offered
        3. 5.2.6.3 Key Developments
        4. 5.2.6.4 SWOT Analysis
        5. 5.2.6.5 Key Strategies
      7. 5.2.7 Accuray (US)
        1. 5.2.7.1 Financial Overview
        2. 5.2.7.2 Products Offered
        3. 5.2.7.3 Key Developments
        4. 5.2.7.4 SWOT Analysis
        5. 5.2.7.5 Key Strategies
      8. 5.2.8 Theragenics Corporation (US)
        1. 5.2.8.1 Financial Overview
        2. 5.2.8.2 Products Offered
        3. 5.2.8.3 Key Developments
        4. 5.2.8.4 SWOT Analysis
        5. 5.2.8.5 Key Strategies
      9. 5.2.9 RMS (US)
        1. 5.2.9.1 Financial Overview
        2. 5.2.9.2 Products Offered
        3. 5.2.9.3 Key Developments
        4. 5.2.9.4 SWOT Analysis
        5. 5.2.9.5 Key Strategies
    3. 5.3 Appendix
      1. 5.3.1 References
      2. 5.3.2 Related Reports
  6. 6 LIST OF FIGURES
    1. 6.1 MARKET SYNOPSIS
    2. 6.2 NORTH AMERICA MARKET ANALYSIS
    3. 6.3 US MARKET ANALYSIS BY MODALITY
    4. 6.4 US MARKET ANALYSIS BY APPLICATION
    5. 6.5 US MARKET ANALYSIS BY TREATMENT TYPE
    6. 6.6 CANADA MARKET ANALYSIS BY MODALITY
    7. 6.7 CANADA MARKET ANALYSIS BY APPLICATION
    8. 6.8 CANADA MARKET ANALYSIS BY TREATMENT TYPE
    9. 6.9 EUROPE MARKET ANALYSIS
    10. 6.10 GERMANY MARKET ANALYSIS BY MODALITY
    11. 6.11 GERMANY MARKET ANALYSIS BY APPLICATION
    12. 6.12 GERMANY MARKET ANALYSIS BY TREATMENT TYPE
    13. 6.13 UK MARKET ANALYSIS BY MODALITY
    14. 6.14 UK MARKET ANALYSIS BY APPLICATION
    15. 6.15 UK MARKET ANALYSIS BY TREATMENT TYPE
    16. 6.16 FRANCE MARKET ANALYSIS BY MODALITY
    17. 6.17 FRANCE MARKET ANALYSIS BY APPLICATION
    18. 6.18 FRANCE MARKET ANALYSIS BY TREATMENT TYPE
    19. 6.19 RUSSIA MARKET ANALYSIS BY MODALITY
    20. 6.20 RUSSIA MARKET ANALYSIS BY APPLICATION
    21. 6.21 RUSSIA MARKET ANALYSIS BY TREATMENT TYPE
    22. 6.22 ITALY MARKET ANALYSIS BY MODALITY
    23. 6.23 ITALY MARKET ANALYSIS BY APPLICATION
    24. 6.24 ITALY MARKET ANALYSIS BY TREATMENT TYPE
    25. 6.25 SPAIN MARKET ANALYSIS BY MODALITY
    26. 6.26 SPAIN MARKET ANALYSIS BY APPLICATION
    27. 6.27 SPAIN MARKET ANALYSIS BY TREATMENT TYPE
    28. 6.28 REST OF EUROPE MARKET ANALYSIS BY MODALITY
    29. 6.29 REST OF EUROPE MARKET ANALYSIS BY APPLICATION
    30. 6.30 REST OF EUROPE MARKET ANALYSIS BY TREATMENT TYPE
    31. 6.31 APAC MARKET ANALYSIS
    32. 6.32 CHINA MARKET ANALYSIS BY MODALITY
    33. 6.33 CHINA MARKET ANALYSIS BY APPLICATION
    34. 6.34 CHINA MARKET ANALYSIS BY TREATMENT TYPE
    35. 6.35 INDIA MARKET ANALYSIS BY MODALITY
    36. 6.36 INDIA MARKET ANALYSIS BY APPLICATION
    37. 6.37 INDIA MARKET ANALYSIS BY TREATMENT TYPE
    38. 6.38 JAPAN MARKET ANALYSIS BY MODALITY
    39. 6.39 JAPAN MARKET ANALYSIS BY APPLICATION
    40. 6.40 JAPAN MARKET ANALYSIS BY TREATMENT TYPE
    41. 6.41 SOUTH KOREA MARKET ANALYSIS BY MODALITY
    42. 6.42 SOUTH KOREA MARKET ANALYSIS BY APPLICATION
    43. 6.43 SOUTH KOREA MARKET ANALYSIS BY TREATMENT TYPE
    44. 6.44 MALAYSIA MARKET ANALYSIS BY MODALITY
    45. 6.45 MALAYSIA MARKET ANALYSIS BY APPLICATION
    46. 6.46 MALAYSIA MARKET ANALYSIS BY TREATMENT TYPE
    47. 6.47 THAILAND MARKET ANALYSIS BY MODALITY
    48. 6.48 THAILAND MARKET ANALYSIS BY APPLICATION
    49. 6.49 THAILAND MARKET ANALYSIS BY TREATMENT TYPE
    50. 6.50 INDONESIA MARKET ANALYSIS BY MODALITY
    51. 6.51 INDONESIA MARKET ANALYSIS BY APPLICATION
    52. 6.52 INDONESIA MARKET ANALYSIS BY TREATMENT TYPE
    53. 6.53 REST OF APAC MARKET ANALYSIS BY MODALITY
    54. 6.54 REST OF APAC MARKET ANALYSIS BY APPLICATION
    55. 6.55 REST OF APAC MARKET ANALYSIS BY TREATMENT TYPE
    56. 6.56 SOUTH AMERICA MARKET ANALYSIS
    57. 6.57 BRAZIL MARKET ANALYSIS BY MODALITY
    58. 6.58 BRAZIL MARKET ANALYSIS BY APPLICATION
    59. 6.59 BRAZIL MARKET ANALYSIS BY TREATMENT TYPE
    60. 6.60 MEXICO MARKET ANALYSIS BY MODALITY
    61. 6.61 MEXICO MARKET ANALYSIS BY APPLICATION
    62. 6.62 MEXICO MARKET ANALYSIS BY TREATMENT TYPE
    63. 6.63 ARGENTINA MARKET ANALYSIS BY MODALITY
    64. 6.64 ARGENTINA MARKET ANALYSIS BY APPLICATION
    65. 6.65 ARGENTINA MARKET ANALYSIS BY TREATMENT TYPE
    66. 6.66 REST OF SOUTH AMERICA MARKET ANALYSIS BY MODALITY
    67. 6.67 REST OF SOUTH AMERICA MARKET ANALYSIS BY APPLICATION
    68. 6.68 REST OF SOUTH AMERICA MARKET ANALYSIS BY TREATMENT TYPE
    69. 6.69 MEA MARKET ANALYSIS
    70. 6.70 GCC COUNTRIES MARKET ANALYSIS BY MODALITY
    71. 6.71 GCC COUNTRIES MARKET ANALYSIS BY APPLICATION
    72. 6.72 GCC COUNTRIES MARKET ANALYSIS BY TREATMENT TYPE
    73. 6.73 SOUTH AFRICA MARKET ANALYSIS BY MODALITY
    74. 6.74 SOUTH AFRICA MARKET ANALYSIS BY APPLICATION
    75. 6.75 SOUTH AFRICA MARKET ANALYSIS BY TREATMENT TYPE
    76. 6.76 REST OF MEA MARKET ANALYSIS BY MODALITY
    77. 6.77 REST OF MEA MARKET ANALYSIS BY APPLICATION
    78. 6.78 REST OF MEA MARKET ANALYSIS BY TREATMENT TYPE
    79. 6.79 KEY BUYING CRITERIA OF HEALTHCARE
    80. 6.80 RESEARCH PROCESS OF MRFR
    81. 6.81 DRO ANALYSIS OF HEALTHCARE
    82. 6.82 DRIVERS IMPACT ANALYSIS: HEALTHCARE
    83. 6.83 RESTRAINTS IMPACT ANALYSIS: HEALTHCARE
    84. 6.84 SUPPLY / VALUE CHAIN: HEALTHCARE
    85. 6.85 HEALTHCARE, BY MODALITY, 2024 (% SHARE)
    86. 6.86 HEALTHCARE, BY MODALITY, 2024 TO 2035 (USD Billion)
    87. 6.87 HEALTHCARE, BY APPLICATION, 2024 (% SHARE)
    88. 6.88 HEALTHCARE, BY APPLICATION, 2024 TO 2035 (USD Billion)
    89. 6.89 HEALTHCARE, BY TREATMENT TYPE, 2024 (% SHARE)
    90. 6.90 HEALTHCARE, BY TREATMENT TYPE, 2024 TO 2035 (USD Billion)
    91. 6.91 BENCHMARKING OF MAJOR COMPETITORS
  7. 7 LIST OF TABLES
    1. 7.1 LIST OF ASSUMPTIONS
  8. 7.1.1
    1. 7.2 North America MARKET SIZE ESTIMATES; FORECAST
      1. 7.2.1 BY MODALITY, 2025-2035 (USD Billion)
      2. 7.2.2 BY APPLICATION, 2025-2035 (USD Billion)
      3. 7.2.3 BY TREATMENT TYPE, 2025-2035 (USD Billion)
    2. 7.3 US MARKET SIZE ESTIMATES; FORECAST
      1. 7.3.1 BY MODALITY, 2025-2035 (USD Billion)
      2. 7.3.2 BY APPLICATION, 2025-2035 (USD Billion)
      3. 7.3.3 BY TREATMENT TYPE, 2025-2035 (USD Billion)
    3. 7.4 Canada MARKET SIZE ESTIMATES; FORECAST
      1. 7.4.1 BY MODALITY, 2025-2035 (USD Billion)
      2. 7.4.2 BY APPLICATION, 2025-2035 (USD Billion)
      3. 7.4.3 BY TREATMENT TYPE, 2025-2035 (USD Billion)
    4. 7.5 Europe MARKET SIZE ESTIMATES; FORECAST
      1. 7.5.1 BY MODALITY, 2025-2035 (USD Billion)
      2. 7.5.2 BY APPLICATION, 2025-2035 (USD Billion)
      3. 7.5.3 BY TREATMENT TYPE, 2025-2035 (USD Billion)
    5. 7.6 Germany MARKET SIZE ESTIMATES; FORECAST
      1. 7.6.1 BY MODALITY, 2025-2035 (USD Billion)
      2. 7.6.2 BY APPLICATION, 2025-2035 (USD Billion)
      3. 7.6.3 BY TREATMENT TYPE, 2025-2035 (USD Billion)
    6. 7.7 UK MARKET SIZE ESTIMATES; FORECAST
      1. 7.7.1 BY MODALITY, 2025-2035 (USD Billion)
      2. 7.7.2 BY APPLICATION, 2025-2035 (USD Billion)
      3. 7.7.3 BY TREATMENT TYPE, 2025-2035 (USD Billion)
    7. 7.8 France MARKET SIZE ESTIMATES; FORECAST
      1. 7.8.1 BY MODALITY, 2025-2035 (USD Billion)
      2. 7.8.2 BY APPLICATION, 2025-2035 (USD Billion)
      3. 7.8.3 BY TREATMENT TYPE, 2025-2035 (USD Billion)
    8. 7.9 Russia MARKET SIZE ESTIMATES; FORECAST
      1. 7.9.1 BY MODALITY, 2025-2035 (USD Billion)
      2. 7.9.2 BY APPLICATION, 2025-2035 (USD Billion)
      3. 7.9.3 BY TREATMENT TYPE, 2025-2035 (USD Billion)
    9. 7.10 Italy MARKET SIZE ESTIMATES; FORECAST
      1. 7.10.1 BY MODALITY, 2025-2035 (USD Billion)
      2. 7.10.2 BY APPLICATION, 2025-2035 (USD Billion)
      3. 7.10.3 BY TREATMENT TYPE, 2025-2035 (USD Billion)
    10. 7.11 Spain MARKET SIZE ESTIMATES; FORECAST
      1. 7.11.1 BY MODALITY, 2025-2035 (USD Billion)
      2. 7.11.2 BY APPLICATION, 2025-2035 (USD Billion)
      3. 7.11.3 BY TREATMENT TYPE, 2025-2035 (USD Billion)
    11. 7.12 Rest of Europe MARKET SIZE ESTIMATES; FORECAST
      1. 7.12.1 BY MODALITY, 2025-2035 (USD Billion)
      2. 7.12.2 BY APPLICATION, 2025-2035 (USD Billion)
      3. 7.12.3 BY TREATMENT TYPE, 2025-2035 (USD Billion)
    12. 7.13 APAC MARKET SIZE ESTIMATES; FORECAST
      1. 7.13.1 BY MODALITY, 2025-2035 (USD Billion)
      2. 7.13.2 BY APPLICATION, 2025-2035 (USD Billion)
      3. 7.13.3 BY TREATMENT TYPE, 2025-2035 (USD Billion)
    13. 7.14 China MARKET SIZE ESTIMATES; FORECAST
      1. 7.14.1 BY MODALITY, 2025-2035 (USD Billion)
      2. 7.14.2 BY APPLICATION, 2025-2035 (USD Billion)
      3. 7.14.3 BY TREATMENT TYPE, 2025-2035 (USD Billion)
    14. 7.15 India MARKET SIZE ESTIMATES; FORECAST
      1. 7.15.1 BY MODALITY, 2025-2035 (USD Billion)
      2. 7.15.2 BY APPLICATION, 2025-2035 (USD Billion)
      3. 7.15.3 BY TREATMENT TYPE, 2025-2035 (USD Billion)
    15. 7.16 Japan MARKET SIZE ESTIMATES; FORECAST
      1. 7.16.1 BY MODALITY, 2025-2035 (USD Billion)
      2. 7.16.2 BY APPLICATION, 2025-2035 (USD Billion)
      3. 7.16.3 BY TREATMENT TYPE, 2025-2035 (USD Billion)
    16. 7.17 South Korea MARKET SIZE ESTIMATES; FORECAST
      1. 7.17.1 BY MODALITY, 2025-2035 (USD Billion)
      2. 7.17.2 BY APPLICATION, 2025-2035 (USD Billion)
      3. 7.17.3 BY TREATMENT TYPE, 2025-2035 (USD Billion)
    17. 7.18 Malaysia MARKET SIZE ESTIMATES; FORECAST
      1. 7.18.1 BY MODALITY, 2025-2035 (USD Billion)
      2. 7.18.2 BY APPLICATION, 2025-2035 (USD Billion)
      3. 7.18.3 BY TREATMENT TYPE, 2025-2035 (USD Billion)
    18. 7.19 Thailand MARKET SIZE ESTIMATES; FORECAST
      1. 7.19.1 BY MODALITY, 2025-2035 (USD Billion)
      2. 7.19.2 BY APPLICATION, 2025-2035 (USD Billion)
      3. 7.19.3 BY TREATMENT TYPE, 2025-2035 (USD Billion)
    19. 7.20 Indonesia MARKET SIZE ESTIMATES; FORECAST
      1. 7.20.1 BY MODALITY, 2025-2035 (USD Billion)
      2. 7.20.2 BY APPLICATION, 2025-2035 (USD Billion)
      3. 7.20.3 BY TREATMENT TYPE, 2025-2035 (USD Billion)
    20. 7.21 Rest of APAC MARKET SIZE ESTIMATES; FORECAST
      1. 7.21.1 BY MODALITY, 2025-2035 (USD Billion)
      2. 7.21.2 BY APPLICATION, 2025-2035 (USD Billion)
      3. 7.21.3 BY TREATMENT TYPE, 2025-2035 (USD Billion)
    21. 7.22 South America MARKET SIZE ESTIMATES; FORECAST
      1. 7.22.1 BY MODALITY, 2025-2035 (USD Billion)
      2. 7.22.2 BY APPLICATION, 2025-2035 (USD Billion)
      3. 7.22.3 BY TREATMENT TYPE, 2025-2035 (USD Billion)
    22. 7.23 Brazil MARKET SIZE ESTIMATES; FORECAST
      1. 7.23.1 BY MODALITY, 2025-2035 (USD Billion)
      2. 7.23.2 BY APPLICATION, 2025-2035 (USD Billion)
      3. 7.23.3 BY TREATMENT TYPE, 2025-2035 (USD Billion)
    23. 7.24 Mexico MARKET SIZE ESTIMATES; FORECAST
      1. 7.24.1 BY MODALITY, 2025-2035 (USD Billion)
      2. 7.24.2 BY APPLICATION, 2025-2035 (USD Billion)
      3. 7.24.3 BY TREATMENT TYPE, 2025-2035 (USD Billion)
    24. 7.25 Argentina MARKET SIZE ESTIMATES; FORECAST
      1. 7.25.1 BY MODALITY, 2025-2035 (USD Billion)
      2. 7.25.2 BY APPLICATION, 2025-2035 (USD Billion)
      3. 7.25.3 BY TREATMENT TYPE, 2025-2035 (USD Billion)
    25. 7.26 Rest of South America MARKET SIZE ESTIMATES; FORECAST
      1. 7.26.1 BY MODALITY, 2025-2035 (USD Billion)
      2. 7.26.2 BY APPLICATION, 2025-2035 (USD Billion)
      3. 7.26.3 BY TREATMENT TYPE, 2025-2035 (USD Billion)
    26. 7.27 MEA MARKET SIZE ESTIMATES; FORECAST
      1. 7.27.1 BY MODALITY, 2025-2035 (USD Billion)
      2. 7.27.2 BY APPLICATION, 2025-2035 (USD Billion)
      3. 7.27.3 BY TREATMENT TYPE, 2025-2035 (USD Billion)
    27. 7.28 GCC Countries MARKET SIZE ESTIMATES; FORECAST
      1. 7.28.1 BY MODALITY, 2025-2035 (USD Billion)
      2. 7.28.2 BY APPLICATION, 2025-2035 (USD Billion)
      3. 7.28.3 BY TREATMENT TYPE, 2025-2035 (USD Billion)
    28. 7.29 South Africa MARKET SIZE ESTIMATES; FORECAST
      1. 7.29.1 BY MODALITY, 2025-2035 (USD Billion)
      2. 7.29.2 BY APPLICATION, 2025-2035 (USD Billion)
      3. 7.29.3 BY TREATMENT TYPE, 2025-2035 (USD Billion)
    29. 7.30 Rest of MEA MARKET SIZE ESTIMATES; FORECAST
      1. 7.30.1 BY MODALITY, 2025-2035 (USD Billion)
      2. 7.30.2 BY APPLICATION, 2025-2035 (USD Billion)
      3. 7.30.3 BY TREATMENT TYPE, 2025-2035 (USD Billion)
    30. 7.31 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
  9. 7.31.1
    1. 7.32 ACQUISITION/PARTNERSHIP
  10. 7.32.1

Healthcare Market Segmentation

Healthcare By Modality (USD Billion, 2025-2035)

  • Intracavitary
  • Interstitial
  • Intraluminal
  • Surface

Healthcare By Application (USD Billion, 2025-2035)

  • Cancer
  • Benign conditions

Healthcare By Treatment Type (USD Billion, 2025-2035)

  • High-dose-rate (HDR) Brachytherapy
  • Low-dose-rate (LDR) Brachytherapy